<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03607682</url>
  </required_header>
  <id_info>
    <org_study_id>VICC THO 1747</org_study_id>
    <secondary_id>NCI-2018-01428</secondary_id>
    <nct_id>NCT03607682</nct_id>
  </id_info>
  <brief_title>Tumor-Treating Fields Therapy in Preventing Brain Tumors in Participants With Extensive-Stage Small Cell Lung Cancer</brief_title>
  <official_title>A Multi-Institutional Pilot Study of Prophylactic Cranial Tumor-Treating Fields for Patients With Extensive-stage Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NovoCure Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies how well tumor-treating fields therapy works in preventing brain tumors in&#xD;
      participants with small cell lung cancer that has spread to other places in the body.&#xD;
      Tumor-treating fields therapy involves the use of the NovoTTF-200A which delivers alternating&#xD;
      electrical fields, or tumor treating fields, through ceramic discs placed on the head. This&#xD;
      electric force may slow and/or reverse tumor growth by disrupting the way cancer cells grow.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To measure the feasibility and compliance of NovoTTF-200A as prophylactic cranial tumor&#xD;
      treatment fields (TTF) therapy, determined by percent (%) of patients continuing TTF therapy&#xD;
      until intracranial tumor progression, discontinuation due to dose limiting toxicity (DLT), or&#xD;
      6 months.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate time to intracranial failure after NovoTTF-200A. II. To evaluate overall&#xD;
      survival after NovoTTF-200A. III. To evaluate the rates of intracranial failure at 2, 4, 6,&#xD;
      8, 10, 12 months after NovoTTF-200A.&#xD;
&#xD;
      IV. To evaluate intracranial failure free survival after NovoTTF-200A. V. To evaluate the&#xD;
      rate of decline in Hopkins Verbal Language Test-Revised (HVLT-R) free recall, delayed recall&#xD;
      and delayed recognition, Controlled Oral Word Association Test (COWAT) and Trail Making Test&#xD;
      (TMT) Parts A and B at 2, 4, 6, 8, 10, 12 months after NovoTTF-200A.&#xD;
&#xD;
      VI. To evaluate time to neurocognitive failure after NovoTTF-200A. VII. To evaluate&#xD;
      neurocognitive failure-free survival after NovoTTF-200A. VIII. To evaluate quality of life&#xD;
      using the European Organization for Research and Treatment of Cancer Quality of Life&#xD;
      Questionnaire Core 30 (EORTC Quality of life Questionnaire C30) with BN20 addendum after&#xD;
      NovoTTF-200A.&#xD;
&#xD;
      IX. To assess adverse events, severity, and frequency associated with NovoTTF-200A using the&#xD;
      Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Participants undergo tumor-treating fields therapy using the NovoTTF-200A device over 18&#xD;
      hours per day for a minimum of 4 weeks and up to 1 year in the absence of disease&#xD;
      progression, unacceptable toxicity, or intracranial failure.&#xD;
&#xD;
      After completion of study treatment, participants are followed up at 8 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI left institution and loss of funding&#xD;
  </why_stopped>
  <start_date type="Actual">September 5, 2018</start_date>
  <completion_date type="Actual">July 13, 2020</completion_date>
  <primary_completion_date type="Actual">June 2, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients Continuing Therapy Until Intracranial Tumor</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Count of patients developed intracranial tumor divided by total number of patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Intracranial Failure</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Time to intracranial failure with death as a competing risk will be estimated using cumulative incidence function (CIF) and reported with a one-sided 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Intracranial Failure</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Estimated using the cumulative incidence function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Decline in Cognitive Function</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Measured by Hopkins Verbal Language Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Neurocognitive Failure</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Measured by Hopkins Verbal Language Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Failure-free Survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Measured by Hopkins Verbal Language Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Quality of Life Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (scale 1-4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Extensive Stage Small Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>Prevention (TTF therapy, NovoTTF-200A device)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tumor Treating Fields (TTF) Therapy</intervention_name>
    <description>Undergo TTF therapy</description>
    <arm_group_label>Prevention (TTF therapy, NovoTTF-200A device)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NovoTTF-200A Device</intervention_name>
    <description>Undergo TTF therapy</description>
    <arm_group_label>Prevention (TTF therapy, NovoTTF-200A device)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Prevention (TTF therapy, NovoTTF-200A device)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Life expectancy of &gt; 3 months&#xD;
&#xD;
          -  Histologically proven extensive stage small cell lung carcinoma (ES-SCLC) (any T any N&#xD;
             and any M stage) within 6 months prior to start of study treatment with the&#xD;
             NovoTTF-200A, with a partial or complete response to at least four cycles of&#xD;
             first-line chemotherapy&#xD;
&#xD;
          -  Karnofsky performance status (KPS) &gt; 70&#xD;
&#xD;
          -  Neutrophil count &gt; 1.5 x 10^9/L&#xD;
&#xD;
          -  Platelet count &gt; 100 x 10^9/L&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) &lt; 2.5 x ULN or&#xD;
             &lt; 5 x ULN if patient has documented liver metastases&#xD;
&#xD;
          -  Serum creatinine &lt; 1.5 x ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of brain metastases on magnetic resonance imaging (MRI) of brain with and&#xD;
             without contrast&#xD;
&#xD;
          -  History of other prior malignancy within the past 5 years except for superficial skin&#xD;
             cancers&#xD;
&#xD;
          -  No severe comorbidities:&#xD;
&#xD;
               -  History of significant cardiovascular disease unless the disease is well&#xD;
                  controlled. Significant cardiac disease includes second/third degree heart block;&#xD;
                  significant ischemic heart disease; poorly controlled hypertension; congestive&#xD;
                  heart failure of the New York Heart Association (NYHA) Class II or worse (slight&#xD;
                  limitation of physical activity; comfortable at rest, but ordinary activity&#xD;
                  results in fatigue, palpitation or dyspnea)&#xD;
&#xD;
               -  History of arrhythmia that is symptomatic or requires treatment. Patients with&#xD;
                  atrial fibrillation or flutter controlled by medication are not excluded from&#xD;
                  participation in the trial&#xD;
&#xD;
               -  History of cerebrovascular accident (CVA) within 6 months prior to start of study&#xD;
                  treatment&#xD;
&#xD;
               -  Active infection or serious underlying medical condition that would impair the&#xD;
                  ability of the patient to receive protocol therapy&#xD;
&#xD;
               -  History of any psychiatric condition that might impair patient's ability to&#xD;
                  understand or comply with the requirements of the study or to provide consent&#xD;
&#xD;
          -  Active implantable electronic medical devices in the brain; a skull defect, a shunt,&#xD;
             or bullet fragments&#xD;
&#xD;
          -  Known allergies to medical adhesives or hydrogel&#xD;
&#xD;
          -  Unable to operate the NovoTTF-200A device independently or with the help of a&#xD;
             caregiver&#xD;
&#xD;
          -  If a female, currently pregnant, breastfeeding, or unwilling to avoid pregnancy while&#xD;
             on study treatment&#xD;
&#xD;
          -  Concurrent brain directed therapy (beyond NovoTTF-200A as per protocol)&#xD;
&#xD;
          -  Prior clinical trial participation with brain directed therapy&#xD;
&#xD;
          -  Concurrent treatment clinical trials&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Attia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 11, 2018</study_first_submitted>
  <study_first_submitted_qc>July 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2018</study_first_posted>
  <results_first_submitted>July 17, 2020</results_first_submitted>
  <results_first_submitted_qc>July 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 4, 2020</results_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Wade Iams</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 6, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT03607682/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This trial was open to accrual from September 2018 to June 2020 at Vanderbilt Medical Center in Nashville, TN. Two participants were enrolled. The study stopped early due to loss of funding.</recruitment_details>
      <pre_assignment_details>2 participants were enrolled; 1 participant had disease progression and was not on the study long enough to be evaluable.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Prevention (TTF Therapy, NovoTTF-200A Device)</title>
          <description>Tumor Treating Fields (TTF) Therapy: Undergo TTF therapy&#xD;
NovoTTF-200A Device: Undergo TTF therapy&#xD;
Quality-of-Life Assessment: Ancillary studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Prevention (TTF Therapy, NovoTTF-200A Device)</title>
          <description>Tumor Treating Fields (TTF) Therapy: Undergo TTF therapy&#xD;
NovoTTF-200A Device: Undergo TTF therapy&#xD;
Quality-of-Life Assessment: Ancillary studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Continuing Therapy Until Intracranial Tumor</title>
        <description>Count of patients developed intracranial tumor divided by total number of patients.</description>
        <time_frame>Up to 6 months</time_frame>
        <population>patients on the therapy</population>
        <group_list>
          <group group_id="O1">
            <title>Prevention (TTF Therapy, NovoTTF-200A Device)</title>
            <description>Tumor Treating Fields (TTF) Therapy: Undergo TTF therapy&#xD;
NovoTTF-200A Device: Undergo TTF therapy&#xD;
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Continuing Therapy Until Intracranial Tumor</title>
          <description>Count of patients developed intracranial tumor divided by total number of patients.</description>
          <population>patients on the therapy</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Intracranial Failure</title>
        <description>Time to intracranial failure with death as a competing risk will be estimated using cumulative incidence function (CIF) and reported with a one-sided 95% confidence interval.</description>
        <time_frame>Up to 3 years</time_frame>
        <population>Data was not collected do to loss of funding.</population>
        <group_list>
          <group group_id="O1">
            <title>Prevention (TTF Therapy, NovoTTF-200A Device)</title>
            <description>Tumor Treating Fields (TTF) Therapy: Undergo TTF therapy&#xD;
NovoTTF-200A Device: Undergo TTF therapy&#xD;
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Intracranial Failure</title>
          <description>Time to intracranial failure with death as a competing risk will be estimated using cumulative incidence function (CIF) and reported with a one-sided 95% confidence interval.</description>
          <population>Data was not collected do to loss of funding.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Estimated using the Kaplan-Meier method.</description>
        <time_frame>Up to 3 years</time_frame>
        <population>Data was not collected do to loss of funding.</population>
        <group_list>
          <group group_id="O1">
            <title>Prevention (TTF Therapy, NovoTTF-200A Device)</title>
            <description>Tumor Treating Fields (TTF) Therapy: Undergo TTF therapy&#xD;
NovoTTF-200A Device: Undergo TTF therapy&#xD;
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Estimated using the Kaplan-Meier method.</description>
          <population>Data was not collected do to loss of funding.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Intracranial Failure</title>
        <description>Estimated using the cumulative incidence function</description>
        <time_frame>Up to 12 months</time_frame>
        <population>Data was not collected do to loss of funding.</population>
        <group_list>
          <group group_id="O1">
            <title>Prevention (TTF Therapy, NovoTTF-200A Device)</title>
            <description>Tumor Treating Fields (TTF) Therapy: Undergo TTF therapy&#xD;
NovoTTF-200A Device: Undergo TTF therapy&#xD;
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Intracranial Failure</title>
          <description>Estimated using the cumulative incidence function</description>
          <population>Data was not collected do to loss of funding.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Decline in Cognitive Function</title>
        <description>Measured by Hopkins Verbal Language Test</description>
        <time_frame>Up to 12 months</time_frame>
        <population>Data was not collected do to loss of funding.</population>
        <group_list>
          <group group_id="O1">
            <title>Prevention (TTF Therapy, NovoTTF-200A Device)</title>
            <description>Tumor Treating Fields (TTF) Therapy: Undergo TTF therapy&#xD;
NovoTTF-200A Device: Undergo TTF therapy&#xD;
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Decline in Cognitive Function</title>
          <description>Measured by Hopkins Verbal Language Test</description>
          <population>Data was not collected do to loss of funding.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Neurocognitive Failure</title>
        <description>Measured by Hopkins Verbal Language Test</description>
        <time_frame>Up to 3 years</time_frame>
        <population>Data was not collected do to loss of funding.</population>
        <group_list>
          <group group_id="O1">
            <title>Prevention (TTF Therapy, NovoTTF-200A Device)</title>
            <description>Tumor Treating Fields (TTF) Therapy: Undergo TTF therapy&#xD;
NovoTTF-200A Device: Undergo TTF therapy&#xD;
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Neurocognitive Failure</title>
          <description>Measured by Hopkins Verbal Language Test</description>
          <population>Data was not collected do to loss of funding.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurocognitive Failure-free Survival</title>
        <description>Measured by Hopkins Verbal Language Test</description>
        <time_frame>Up to 3 years</time_frame>
        <population>Data was not collected do to loss of funding.</population>
        <group_list>
          <group group_id="O1">
            <title>Prevention (TTF Therapy, NovoTTF-200A Device)</title>
            <description>Tumor Treating Fields (TTF) Therapy: Undergo TTF therapy&#xD;
NovoTTF-200A Device: Undergo TTF therapy&#xD;
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Failure-free Survival</title>
          <description>Measured by Hopkins Verbal Language Test</description>
          <population>Data was not collected do to loss of funding.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate Quality of Life Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30</title>
        <description>Measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (scale 1-4)</description>
        <time_frame>Up to 3 years</time_frame>
        <population>Data was not collected do to loss of funding.</population>
        <group_list>
          <group group_id="O1">
            <title>Prevention (TTF Therapy, NovoTTF-200A Device)</title>
            <description>Tumor Treating Fields (TTF) Therapy: Undergo TTF therapy&#xD;
NovoTTF-200A Device: Undergo TTF therapy&#xD;
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate Quality of Life Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30</title>
          <description>Measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (scale 1-4)</description>
          <population>Data was not collected do to loss of funding.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Events</title>
        <description>Graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</description>
        <time_frame>Up to 12 months</time_frame>
        <population>Patients on the therapy</population>
        <group_list>
          <group group_id="O1">
            <title>Prevention (TTF Therapy, NovoTTF-200A Device)</title>
            <description>Tumor Treating Fields (TTF) Therapy: Undergo TTF therapy&#xD;
NovoTTF-200A Device: Undergo TTF therapy&#xD;
Quality-of-Life Assessment: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events</title>
          <description>Graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</description>
          <population>Patients on the therapy</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The adverse event reporting period began immediately following registration to treatment (start of use of the NovoTTF-200A device). Adverse events were collected for 8 weeks following treatment termination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Prevention (TTF Therapy, NovoTTF-200A Device)</title>
          <description>Tumor Treating Fields (TTF) Therapy: Undergo TTF therapy&#xD;
NovoTTF-200A Device: Undergo TTF therapy&#xD;
Quality-of-Life Assessment: Ancillary studies</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Teresa Melton</name_or_title>
      <organization>Vanderbilt University Medical Center</organization>
      <phone>6159367423</phone>
      <email>teresa.melton@vumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

